Immune reconstitution and viral infections after stem cell transplantation

Bone Marrow Transplantation

Volumn 21, Issue SUPPL. 2, 1998, Pages

  Ljungman, P ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

CMV; HHV 6; Respiratory viruses; SCT

Indexed keywords

ANTIVIRUS AGENT; GANCICLOVIR; IMMUNOGLOBULIN;

CONFERENCE PAPER; CYTOMEGALOVIRUS; DRUG TOXICITY; EARLY DIAGNOSIS; EPSTEIN BARR VIRUS; FATALITY; GRAFT VERSUS HOST REACTION; HERPES VIRUS; HUMAN; IMMUNE STATUS; INFLUENZA VIRUS; INTRAVENOUS DRUG ADMINISTRATION; PARAINFLUENZA VIRUS; PRIORITY JOURNAL; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; RISK FACTOR; STEM CELL TRANSPLANTATION; T LYMPHOCYTE; VIRUS INFECTION;

CYTOMEGALOVIRUS INFECTIONS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HERPESVIRIDAE INFECTIONS; HERPESVIRUS 6, HUMAN; HUMANS; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS; T-LYMPHOCYTES;

EID: 0031922920     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (22)

1. Reusser P, Cordonnier C, Einsele H et al. European survey of herpesvirus resistance to antiviral drugs in bone marrow transplant recipients. Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation (EBMT). Bone Marrow Transplant 1996; 17: 813-817.
2. Ljungman P. Respiratory virus infections in bone marrow transplant recipients: The European perspective. Am J Med 1997; 102 (suppl 3A).
3. Whimbey E, Englund J, Couch R. Community respiratory virus infections in immunocompromised patients with cancer. Am J Med 1997; 102 (suppl 3A): 10-18.
4. Whimbey E, Champlin R, Englund J et al. Combination therapy with aerosolized ribavirin and intravenous immunoglobulin for respiratory syncytial virus disease in adult bone marrow transplant recipients. Bone Marrow Transplant 1995; 16: 393-399.
5. Sparrelid E, Ljungman P, Ekelöf-Andström E et al. Ribavirin therapy in bone marrow transplant recipients with respiratory tract infections. Bone Marrow Transplant 1997; 19: 905-908.
6. Lewinsohn D, Bowden R, Matsson D et al. Phase I study of intravenous ribavirin treatment of respiratory syncytial virus pneumonia after marrow transplantation. Antimicrob Agents Chemother 1996; 40: 2555-2557.
7. Wendt C, Weisdorf D, Jordan M et al. Parainfluenza virus respiratory infection after bone marrow transplantation. New Engl J Med 1992; 326: 921-926.
8. Lewis V, Champlin R, Englund J et al. Respiratory disease due to parainfluenza virus in adult bone marrow transplant recipients. Clin Infect Dis 1996; 23: 1033-1037.
9. Meyers J, Reed E, Shepp D et al. Acyclovir for prevention of CMV infection and disease after allogeneic marrow transplantation. N Eng J Med 1988; 318: 70-75.
10. Prentice HG, Gluckman E, Powles RL et al. Impact of long-term acyclovir on cytomegalovirus infection and survival after allogeneic bone marrow transplantation. European Acyclovir for CMV Prophylaxis Study Group. Lancet 1994; 343: 749-53.
11. Goodrich J, Bowden R, Fisher L et al. Ganciclovir prophylaxis to prevent cytomegalovirus disease after allogeneic marrow transplant. Ann Intern Med 1993; 118: 173-178.
12. Winston D, Ho W, Bartoni K et al. Ganciclovir prophylaxis of cytomegalovirus infection and disease in allogeneic bone marrow transplant recipients. Ann Intern Med 1993; 118: 179-184.
13. Boeckh M, Riddell S, Cunningham T et al. Increased risk of late CMV infection and disease in allogeneic marrow transplant recipients after ganciclovir prophylaxis is due to a lack of CMV-specific f cell responses. Blood 1996; 88 (suppl 1): 302a.
14. Einsele H, Ehninger G, Hebart H et al. Polymerase chain reaction monitoring reduces the incidence of cytomegalovirus disease and the duration and side effects of antiviral therapy after bone marrow transplantation. Blood 1995; 86: 2815-2820.
15. Ljungman P, Loré K, Aschan J et al. Use of a semi-quantitative PCR for cytomegalovirus DNA as basis for preemptive therapy in allogeneic bone marrow transplant recipients. Bone Marrow Transplant 1996; 17: 583-587.
16. Carrigan DR, Drobyski WR, Russler SK et al. Interstitial pneumonitis associated with human herpesvirus-6 infection after marrow transplantation. Lancet 1991; 338: 147-149.
17. Ljungman P, Wang F-Z, Linde A et al. Human herpesvirus type 6 (HHV-6) encephalitis in allogeneic BMT recipients. Blood 1997; 90 (suppl 1): 543a.
18. Carrigan DR, Knox KK. Human herpesvirus 6 (HHV-6) isolation from bone marrow: HHV-6-associated bone marrow suppression in bone marrow transplant patients. Blood 1994; 84: 3307-3310.
19. Wang FZ, Dahl H, Linde A et al. Lymphotropic herpesviruses in allogeneic bone marrow transplantation. Blood 1996; 88: 3615-3620.
20. Li CR, Greenberg PD, Gilbert MJ et al. Recovery of HLA-restricted cytomegalovirus (CMV)-specific T-cell responses after allogeneic bone marrow transplant: correlation with CMV disease and effect of ganciclovir prophylaxis. Blood 1994; 83: 1971-1979.
21. Walter EA, Greenberg PD, Gilbert MJ et al. Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor. N Engl J Med 1995; 333: 1038-1044.
22. Rooney CM, Smith CA, Ng CY et al. Use of gene-modified virus-specific T lymphocytes to control Epstein-Barr-virus-related lymphoproliferation. Lancet 1995; 345: 9-13.